potassium chloride | Potassium chloride buffus Renewal conc. for preparation. solution for infusion 4% 10 ml ampoules 10 pcs.
Special Price
$11.96
Regular Price
$22.00
In stock
SKU
BID471828
Release form
Concentrate for solution for infusion.
Concentrate for solution for infusion.
Release form
Concentrate for solution for infusion.
Packing
10 pcs.
Pharmacological action
POTASSIUM CHLORIDE BUFUS - K + preparation, restores water-electrolyte balance. It has a negative chrono- and batmotropic effect, in high doses - negative foreign and dromotropic, as well as moderate diuretic effect.
In small doses, K + dilates the coronary vessels, in large doses it narrows. Participates in the process of conducting nerve impulses. When administered intravenously increases the excretion of epinephrine by the adrenal glands.
Activates many cytoplasmic enzymes, is involved in maintaining intracellular osmotic pressure, in protein-synthetic reactions and in the transport of amino acids.
Improves skeletal muscle contraction during muscular dystrophy, myasthenia gravis. Increasing the concentration of K + reduces the risk of toxic effects of cardiac glycosides.
Contraindications
Hyperkalemia, complete atrioventricular block, adrenal insufficiency, chronic renal failure, concomitant therapy with potassium-sparing diuretics, metabolic disorders (acidosis, hypovolemia with hyponatremia), pregnancy, lactation age up to 18 years (efficacy and safety not established).
Use during pregnancy and lactation
If necessary during pregnancy, the expected benefits for the mother should be weighed and the potential risk to the fetus during lactation should the issue of cessation of breastfeeding be resolved.
Special instructions
During treatment, it is necessary to control the content of K + in the blood serum, ECG, and in the treatment of hypokalemia, control of the acid-base state.
Safety and efficacy of potassium chloride in children have not been established.
If necessary, use during pregnancy should compare the expected benefits to the mother and the potential risk to the fetus.
During lactation, the issue of stopping breastfeeding should be decided. A diet high in sodium chloride increases K + excretion from the body.
It should be borne in mind that hyperkalemia leading to death can develop quickly and be asymptomatic.
Composition of
1 ml of solution contains:
Active ingredient:
potassium chloride 40 mg.
Excipients:
dextrose,
hydrochloric acid (0.1 M hydrochloric acid solution),
water for injection.
Dosing and Administration
Intravenously With hypokalemia with a violation of the heart rhythm - 1-1.5 g 4-5 times a day after the restoration of heart rhythm, the dose is reduced. With digitalis intoxication - 2-3 g / day, in severe cases - up to 5 g.
For the relief of paroxysmal tachycardia attacks on the first day - 8-12 g, followed by a decrease to 3-6 g.
Intravenously, if necessary, intravenously dropwise (slowly, over 1 hour) - 2-2.5 g in 500 ml of 5% dextrose solution. For the prevention of treatment of ectopic arrhythmias with myocardial infarction - a polarizing mixture: a solution of potassium chloride in a 5% -10% dextrose solution (add insulin at the rate of 1 unit per 3-4 g of dry dextrose).
Side effects
From the nervous system: paresthesia, muscle weakness, confusion.
From the cardiovascular system: lowering blood pressure, arrhythmias, heart block, cardiac arrest.
Other: hyperkalemia, allergic reactions.
Drug Interactions
Pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerance).
Enhances the negative dromo- and batmotropic effects of antiarrhythmic drugs.
As part of a polarizing mixture (in combination with dextrose and insulin), it helps normalize heart rhythm in myocardial infarction, ectopic arrhythmias and an overdose of cardiac glycosides.
Eliminates hypokalemia, caused by glucocorticosteroids, mineralocorticosteroids and diuretics.
Beta-blockers, cyclosporine, potassium-sparing diuretics, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs can increase the risk of hyperkalemia.
Overdose
Symptoms: hyperkalemia (muscle hypotension, limb paresthesias, slowing atrioventricular conduction, arrhythmias, cardiac arrest).
Early clinical signs of hyperkalemia usually occur at a serum K + concentration of more than 6 mEq / l: sharpening of the T-tooth, disappearance of the U-tooth, decrease of the ST segment, extension of the QT interval, expansion of the QRS complex. More severe symptoms of hyperkalemia - muscle paralysis and cardiac arrest - develop at a concentration of K + 9-10 mEq / l.
Treatment: intravenously or intravenously - NaCl solution intravenously - 300-500 ml of 5% dextrose solution (with 10-20 IU insulin in 1 l) if necessary - hemodialysis and peritoneal dialysis.
Storage Conditions
In a dry, dark place at 0 to +30 РC.
Shelf life
3 years. Do not use after expiration date.
Terms and conditions
prescription
Dosage form
infusion solution
Possible product names
Potassium chloride buffus Renewal conc. for preparation. solution for infusion 4% 10 ml ampoules 10 pcs.
Potassium chloride Bufus ampoules 4%, 10 ml, 10 pcs.
POTASSIUM CHLORIDE BUFUS END. Prigot. R-RA D / INF. 40MG / ML AMP. POLYMER. 10ML №10 (01.14)
Potassium chloride Bufus solution for inf 4% 10ml N10 Renewal (PARTY 2pcs)
PFK Update, Russia
Concentrate for solution for infusion.
Packing
10 pcs.
Pharmacological action
POTASSIUM CHLORIDE BUFUS - K + preparation, restores water-electrolyte balance. It has a negative chrono- and batmotropic effect, in high doses - negative foreign and dromotropic, as well as moderate diuretic effect.
In small doses, K + dilates the coronary vessels, in large doses it narrows. Participates in the process of conducting nerve impulses. When administered intravenously increases the excretion of epinephrine by the adrenal glands.
Activates many cytoplasmic enzymes, is involved in maintaining intracellular osmotic pressure, in protein-synthetic reactions and in the transport of amino acids.
Improves skeletal muscle contraction during muscular dystrophy, myasthenia gravis. Increasing the concentration of K + reduces the risk of toxic effects of cardiac glycosides.
Contraindications
Hyperkalemia, complete atrioventricular block, adrenal insufficiency, chronic renal failure, concomitant therapy with potassium-sparing diuretics, metabolic disorders (acidosis, hypovolemia with hyponatremia), pregnancy, lactation age up to 18 years (efficacy and safety not established).
Use during pregnancy and lactation
If necessary during pregnancy, the expected benefits for the mother should be weighed and the potential risk to the fetus during lactation should the issue of cessation of breastfeeding be resolved.
Special instructions
During treatment, it is necessary to control the content of K + in the blood serum, ECG, and in the treatment of hypokalemia, control of the acid-base state.
Safety and efficacy of potassium chloride in children have not been established.
If necessary, use during pregnancy should compare the expected benefits to the mother and the potential risk to the fetus.
During lactation, the issue of stopping breastfeeding should be decided. A diet high in sodium chloride increases K + excretion from the body.
It should be borne in mind that hyperkalemia leading to death can develop quickly and be asymptomatic.
Composition of
1 ml of solution contains:
Active ingredient:
potassium chloride 40 mg.
Excipients:
dextrose,
hydrochloric acid (0.1 M hydrochloric acid solution),
water for injection.
Dosing and Administration
Intravenously With hypokalemia with a violation of the heart rhythm - 1-1.5 g 4-5 times a day after the restoration of heart rhythm, the dose is reduced. With digitalis intoxication - 2-3 g / day, in severe cases - up to 5 g.
For the relief of paroxysmal tachycardia attacks on the first day - 8-12 g, followed by a decrease to 3-6 g.
Intravenously, if necessary, intravenously dropwise (slowly, over 1 hour) - 2-2.5 g in 500 ml of 5% dextrose solution. For the prevention of treatment of ectopic arrhythmias with myocardial infarction - a polarizing mixture: a solution of potassium chloride in a 5% -10% dextrose solution (add insulin at the rate of 1 unit per 3-4 g of dry dextrose).
Side effects
From the nervous system: paresthesia, muscle weakness, confusion.
From the cardiovascular system: lowering blood pressure, arrhythmias, heart block, cardiac arrest.
Other: hyperkalemia, allergic reactions.
Drug Interactions
Pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerance).
Enhances the negative dromo- and batmotropic effects of antiarrhythmic drugs.
As part of a polarizing mixture (in combination with dextrose and insulin), it helps normalize heart rhythm in myocardial infarction, ectopic arrhythmias and an overdose of cardiac glycosides.
Eliminates hypokalemia, caused by glucocorticosteroids, mineralocorticosteroids and diuretics.
Beta-blockers, cyclosporine, potassium-sparing diuretics, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs can increase the risk of hyperkalemia.
Overdose
Symptoms: hyperkalemia (muscle hypotension, limb paresthesias, slowing atrioventricular conduction, arrhythmias, cardiac arrest).
Early clinical signs of hyperkalemia usually occur at a serum K + concentration of more than 6 mEq / l: sharpening of the T-tooth, disappearance of the U-tooth, decrease of the ST segment, extension of the QT interval, expansion of the QRS complex. More severe symptoms of hyperkalemia - muscle paralysis and cardiac arrest - develop at a concentration of K + 9-10 mEq / l.
Treatment: intravenously or intravenously - NaCl solution intravenously - 300-500 ml of 5% dextrose solution (with 10-20 IU insulin in 1 l) if necessary - hemodialysis and peritoneal dialysis.
Storage Conditions
In a dry, dark place at 0 to +30 РC.
Shelf life
3 years. Do not use after expiration date.
Terms and conditions
prescription
Dosage form
infusion solution
Possible product names
Potassium chloride buffus Renewal conc. for preparation. solution for infusion 4% 10 ml ampoules 10 pcs.
Potassium chloride Bufus ampoules 4%, 10 ml, 10 pcs.
POTASSIUM CHLORIDE BUFUS END. Prigot. R-RA D / INF. 40MG / ML AMP. POLYMER. 10ML №10 (01.14)
Potassium chloride Bufus solution for inf 4% 10ml N10 Renewal (PARTY 2pcs)
PFK Update, Russia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review